{"uid":"cap_Yj5qpaEnkbqHw6pscBrMt","slug":"clinicalintelpulse-trial-brief-a0256c9e","name":"ClinicalIntelPulse Trial Brief","description":"Clinical trial deep dive by NCT ID — full trial design, primary/secondary endpoints, enrollment status and countries, sponsor, recruitment criteria, outcomes and publications for any ClinicalTrials.gov study. For research and biotech agents.","url":"https://clinicalintelpulse.theaslangroupllc.com/api/clinical/trial-brief","method":"GET","headers":{},"bodySchema":{"type":"object","$schema":"https://json-schema.org/draft/2020-12/schema","required":["input"],"properties":{"input":{"type":"object","required":["type","method"],"properties":{"type":{"type":"string","const":"http"},"method":{"enum":["GET","HEAD","DELETE"],"type":"string"},"queryParams":{"type":"object","properties":{"lang":{"type":"string"},"nct_id":{"type":"string"}}}},"additionalProperties":false},"output":{"type":"object","required":["type"],"properties":{"type":{"type":"string"},"errors":{"type":"object","description":"Documented error responses, keyed by HTTP status code","additionalProperties":{"type":"object","required":["description"],"properties":{"example":{"type":"object"},"description":{"type":"string"}}}},"example":{"type":"object"}}}}},"responseSchema":{"type":"json","example":{"design":{"arms":["Tiragolumab + Atezolizumab + Carboplatin/Paclitaxel","Placebo + Atezolizumab + Carboplatin/Paclitaxel"],"masking":"Double-Blind","allocation":"Randomized","study_type":"INTERVENTIONAL","primary_purpose":"Treatment"},"endpoints":{"primary":["Progression-Free Survival (PFS)","Overall Survival (OS)"],"secondary":["Objective Response Rate","Duration of Response","Safety/Tolerability"]},"enrollment":{"actual":534,"planned":534,"countries":["United States","Spain","Germany","Japan","Australia"]},"interventions":[{"name":"Tiragolumab","role":"Anti-TIGIT immune checkpoint inhibitor","type":"DRUG"}],"query_summary":{"nct_id":"NCT04368728","retrieved_from":"ClinicalTrials.gov v2 API"},"trial_identity":{"phase":"PHASE3","title":"A Study of Tiragolumab in Combination With Atezolizumab and Chemotherapy Versus Placebo in Untreated Locally Advanced Unresectable or Metastatic NSCLC (SKYSCRAPER-01)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","start_date":"2019-06","primary_completion":"2022-12"},"outcome_summary":"SKYSCRAPER-01 failed to meet primary PFS endpoint (HR 0.93). Significant negative readout for anti-TIGIT in NSCLC.","regulatory_implications":"Setback for Roche tiragolumab program. Broader TIGIT class facing headwinds."}},"example":null,"exampleRequest":null,"tags":["x402"],"displayCostAmount":"0.1","displayCostAsset":"USDC","priceDynamic":false,"priceHint":null,"priceStatus":"priced","priceSource":"probe","requiresHandshake":false,"reviewCount":0,"rating":{"score":"0.00","successRate":"0.00","reviews":0,"stars":null,"state":"unrated"},"availabilityStatus":"unknown","priceObserved":null,"sessionDeposit":null,"pricing":{"kind":"static","summary":"$0.1/call","primary":{"kind":"static","protocol":"x402","network":"base","amountUsd":"0.1","per":"call","confidence":"exact"},"accepted":[{"kind":"static","protocol":"x402","network":"base","amountUsd":"0.1","per":"call","confidence":"exact"}]},"paymentMethods":[{"uid":"pm_2tXQ-VFd3ffYGCg6FlV2H","protocol":"x402","methodType":"crypto","chain":"base","mode":"charge","costAmount":"0.1","costPer":"request","priority":0,"asset":"0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913","unit":"request","depositMicros":null,"planRef":null}],"brandName":null,"brandSlug":null,"brandBaseUrl":null,"brandDocsUrl":null,"whatItDoes":"Retrieves a comprehensive deep-dive profile of a specific ClinicalTrials.gov study by NCT ID, including trial design, endpoints, enrollment, sponsor, and publications.","exampleAgentPrompt":"Pull the full trial brief for NCT04280705 — I need the trial design, primary and secondary endpoints, enrollment status, recruiting countries, sponsor, and any published outcomes.","exampleUseCases":null,"resultDescription":"A structured profile of the clinical trial including: trial design and phase, primary and secondary endpoints, current enrollment status and target enrollment numbers, list of participating countries, sponsor and collaborator names, inclusion/exclusion recruitment criteria, outcome measures, and linked publications.","failureModes":["Invalid or malformed NCT ID returns a 400 or not-found error","NCT ID not yet indexed in ClinicalTrials.gov returns empty or null result","Trial record has minimal data (e.g. newly registered study) resulting in sparse output","Payment authorization failure via x402 protocol returns 402","Rate limiting or upstream ClinicalTrials.gov API downtime causes timeout"],"whenToPreferThis":"Use this endpoint when you need a deep, structured profile of a single known clinical trial and already have its NCT ID. It is ideal for research agents, biotech analysts, and competitive intelligence workflows that need granular trial-level data including endpoints, recruitment details, and publications — rather than a broad disease-level landscape view.","instructions":null,"reviewSummary":null,"reviewSummaryHighlights":null,"reviewSummaryConcerns":null,"reviewSummaryGeneratedAt":null,"activationCount":0,"lastUsedAt":null,"lastSuccessfullyRanAt":null,"lastHealthCheckAt":"2026-09-15T12:39:17.329Z","isFirstParty":false}